Aethlon Medical Inc (AEMD)

[oddone33320]

Aethlon's Study Details on Clinicaltrials.gov

Further study details as provided by Aethlon Medical Inc.:

Primary Outcome Measures:
Rate of adverse events [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
Viral load reduction [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
Viral load will be measured before and after each treatment with the investigational device.


Other Outcome Measures:
Quantification of viral copies captured. [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
The number of viral copies captured by the Aethlon Hemopurifier® during the first and last Hemopurifier treatments will be quantified.


Estimated Enrollment: 10
Study Start Date: December 2014
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)